Illumina, Inc.
ILMN
Rank in Stocks
#612
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis... Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Share Price
$262.37
Last synced: 2026-10-19
Market Cap
$39.62B
Change (1 day)
-0.07%
Change (1 year)
163.68%
Country
US
Trade Illumina, Inc. (ILMN)
Category
Healthcare
P/E ratio for Illumina, Inc. (ILMN)
P/E ratio as of October 2026 TTM: 50.23
According to Illumina, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 50.23. At the end of 2024 the company had a P/E ratio of -17.37.
P/E ratio history for Illumina, Inc. from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 50.23 | 112.76% |
| 2025 | 23.61 | -235.95% |
| 2024 | -17.37 | -5.70% |
| 2023 | -18.42 | -125.27% |
| 2022 | 72.86 | -9.02% |
| 2021 | 80.09 | 71.18% |
| 2019 | 46.78 | -9.81% |
| 2018 | 51.87 | 21.48% |
| 2017 | 42.70 | -22.84% |
| 2016 | 55.34 | -21.67% |
| 2014 | 70.66 | -33.90% |
| 2013 | 106.90 | 143.35% |
| 2012 | 43.93 | -29.00% |
| 2011 | 61.87 | 22.31% |
| 2010 | 50.59 | -9.48% |
| 2008 | 55.88 | -598.71% |
| 2007 | -11.21 | -126.35% |
| 2006 | 42.53 | -182.07% |
| 2005 | -51.82 | 525.80% |
| 2003 | -8.28 | 242.16% |
| 2002 | -2.42 | -82.32% |
| 2001 | -13.69 | -41.39% |
| 2000 | -23.35 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 36.15 | -28.03% |
US
|
|
| 39.77 | -20.82% |
US
|
|
| -290.26 | -677.82% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -31.95% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.